Vulvovaginal Candidiasis Treatment Market 2030: Unpacking the Latest Advances
Vulvovaginal Candidiasis (VVC) Treatment Market Overview The global vulvovaginal candidiasis (VVC) treatment market was valued at USD 986.5 million in 2021 and is projected to reach USD 1.64 billion by 2030, expanding at a CAGR of 4.39% from 2022 to 2030. VVC is a widespread fungal infection affecting approximately 138 million women annually worldwide, according to a report published by NCBI. The market is being driven by a rising disease burden, a robust pipeline, and the launch of new treatments, including BREXAFEMME and VIVJOA, which mark significant advancements in disease management. Globally, around 75% of women experience VVC at least once in their lifetime. Of these, 10–20% suffer from complicated VVC, while 9% report recurrent infections. Additionally, 15% of cases require special therapeutic approaches, reflecting the complexity of managing certain patient groups. Rising antibiotic resistance and the increasing prevalence of diabetes are further contributing to the g...